國立虎尾科技大學 |

Myelodysplastic Syndromes = Diagnosis - Prognosis - Therapy /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Myelodysplastic Syndromes / edited by Uwe Platzbecker, Pierre Fenaux.
Reminder of title:	Diagnosis - Prognosis - Therapy /
other author:	Platzbecker, Uwe.
Description:	V, 157 p. 26 illus., 22 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Hematology. -
Online resource:	https://doi.org/10.1007/978-3-319-76879-3
ISBN:	9783319768793

Myelodysplastic Syndromes = Diagnosis - Prognosis - Therapy /
Myelodysplastic Syndromes Diagnosis - Prognosis - Therapy /[electronic resource] :edited by Uwe Platzbecker, Pierre Fenaux. - 1st ed. 2018. - V, 157 p. 26 illus., 22 illus. in color.online resource. - Hematologic Malignancies,2197-9766. - Hematologic Malignancies,.

Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. .

This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.

ISBN: 9783319768793

Standard No.: 10.1007/978-3-319-76879-3doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Myelodysplastic Syndromes = Diagnosis - Prognosis - Therapy /
LDR:02982nam a22004095i 4500 001 994468
003 DE-He213
005 20200629201559.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319768793 $9 978-3-319-76879-3
024 7 $a 10.1007/978-3-319-76879-3 $2 doi
035 $a 978-3-319-76879-3
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Myelodysplastic Syndromes $h [electronic resource] : $b Diagnosis - Prognosis - Therapy / $c edited by Uwe Platzbecker, Pierre Fenaux.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a V, 157 p. 26 illus., 22 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Hematologic Malignancies, $x 2197-9766
505 0 $a Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. .
520 $a This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
650 0 $a Hematology. $3 645254
650 0 $a Oncology . $3 1253469
650 2 4 $a Oncology. $3 593951
700 1 $a Platzbecker, Uwe. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1206497
700 1 $a Fenaux, Pierre. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1206498
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319768786
776 0 8 $i Printed edition: $z 9783319768809
776 0 8 $i Printed edition: $z 9783030083168
830 0 $a Hematologic Malignancies, $x 2197-9766 $3 1253495
856 4 0 $u https://doi.org/10.1007/978-3-319-76879-3
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)